je.st
news
Tag: in
Less than 2 months in, car2go has more than 78K customers in Chongqing
2016-06-07 19:56:44| Green Car Congress
Tags: in
than
months
customers
KPN outperforms as Dutch mobile market contracts 3% in Q1
2016-06-07 09:45:00| Telecompaper Headlines
(Telecompaper) KPN outperforms as Dutch mobile market contracts 3.0% in Q1 2016 The Dutch mobile services market generated EUR 1.11 billion in revenue in the first quarter of 2016, a drop of 3.0 percent compared to the same quarter last year and a decline of 2.9 percent versus the fourth quarter of 2015. According to Telecompaper's latest quarterly mobile market monitor, the four network providers continued to see some price pressure due to strong competition and lower out-of-bundle revenues. Both T-Mobile and Vodafone experienced a drop in annual mobile service revenues and as such they lost market share. In contrast, KPN showed an annual revenue growth which reinforced its market share. Tele2 also showed growth but remains the smallest player.
Tiny 2-Way 0° MMIC Splitter/Combiners Cover 0.5 To 9.5 GHz In 5x5mm Packages
2016-06-07 05:51:39| rfglobalnet Home Page
To meet your needs for even more applications, Mini-Circuits has added two new models to our popular EP-series of ultra-wideband MMIC splitter/combiners extending frequency coverage down to 0.5 GHz.
As a worker the Great Barrier Reef I'm ashamed to look my children in the eye
2016-06-07 01:37:00| Climate Ark Climate Change & Global Warming Newsfeed
Guardian: As a marine ecologist who has been working on the Great Barrier Reef for 30 years I am today still stunned, often tearful, and ashamed to look my children in the eye. The Great Barrier Reef is undergoing change that means it will never be the same again in my lifetime. It will take decades to regrow. To put this in a global perspective, considering the reef as a whole, an area of the reef the size of Scotland has coral in it that is largely dead. If most or all the coral on a reef bleaches...
KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 11:30 a.m. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [473] [474] [475] [476] [477] [478] [479] [480] [481] [482] [483] [484] [485] [486] [487] [488] [489] [490] [491] [492] next »